JP4572195B2 - ８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体 - Google Patents

８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体 Download PDF

Info

Publication number
JP4572195B2
JP4572195B2 JP2006505152A JP2006505152A JP4572195B2 JP 4572195 B2 JP4572195 B2 JP 4572195B2 JP 2006505152 A JP2006505152 A JP 2006505152A JP 2006505152 A JP2006505152 A JP 2006505152A JP 4572195 B2 JP4572195 B2 JP 4572195B2
Authority
JP
Japan
Prior art keywords
phenyl
group
tetrahydro
pyrimido
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006505152A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006520767A (ja
JP2006520767A5 (enExample
Inventor
ロシャード，アリステア
サアーディ，ムラ
スロウィンスキ，フランク
ヤイシェ，フィリップ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Mitsubishi Tanabe Pharma Corp
Original Assignee
Sanofi Synthelabo SA
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA, Mitsubishi Tanabe Pharma Corp filed Critical Sanofi Synthelabo SA
Publication of JP2006520767A publication Critical patent/JP2006520767A/ja
Publication of JP2006520767A5 publication Critical patent/JP2006520767A5/ja
Application granted granted Critical
Publication of JP4572195B2 publication Critical patent/JP4572195B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2006505152A 2003-03-21 2004-03-19 ８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体 Expired - Fee Related JP4572195B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290727A EP1460075A1 (en) 2003-03-21 2003-03-21 Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
PCT/EP2004/004014 WO2004082577A2 (en) 2003-03-21 2004-03-19 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES

Publications (3)

Publication Number Publication Date
JP2006520767A JP2006520767A (ja) 2006-09-14
JP2006520767A5 JP2006520767A5 (enExample) 2007-05-10
JP4572195B2 true JP4572195B2 (ja) 2010-10-27

Family

ID=32799140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505152A Expired - Fee Related JP4572195B2 (ja) 2003-03-21 2004-03-19 ８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体

Country Status (25)

Country Link
US (2) US7247638B2 (enExample)
EP (2) EP1460075A1 (enExample)
JP (1) JP4572195B2 (enExample)
KR (1) KR101070149B1 (enExample)
CN (1) CN100358897C (enExample)
AR (1) AR043658A1 (enExample)
AT (1) ATE452892T1 (enExample)
AU (1) AU2004222596B2 (enExample)
BR (1) BRPI0408591A (enExample)
CA (1) CA2518299C (enExample)
CY (1) CY1109890T1 (enExample)
DE (1) DE602004024770D1 (enExample)
DK (1) DK1608654T3 (enExample)
EA (1) EA009197B1 (enExample)
ES (1) ES2338325T3 (enExample)
IL (1) IL170680A (enExample)
MX (1) MXPA05010158A (enExample)
NO (1) NO20054330L (enExample)
NZ (1) NZ542380A (enExample)
PL (1) PL1608654T3 (enExample)
PT (1) PT1608654E (enExample)
SI (1) SI1608654T1 (enExample)
TW (1) TWI330186B (enExample)
WO (1) WO2004082577A2 (enExample)
ZA (1) ZA200507487B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP1939187A1 (en) * 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
TWI838401B (zh) 2018-09-12 2024-04-11 瑞士商諾華公司 抗病毒性吡啶并吡𠯤二酮化合物
TWI867053B (zh) 2019-09-26 2024-12-21 瑞士商諾華公司 抗病毒吡唑并吡啶酮化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001270884A (ja) * 2000-03-23 2001-10-02 Mitsubishi-Tokyo Pharmaceuticals Inc ピリミドン誘導体
EP1136482A1 (en) * 2000-03-23 2001-09-26 Sanofi-Synthelabo 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors
ATE269333T1 (de) * 2000-09-01 2004-07-15 Sanofi Synthelabo 2-pyridinyl-6,7,8,9-tetrahydropyrimido(1,2- a)pyrimidin-4-on- und 7-pyridinyl-2,3- dihydroimidazo(1,2-a)pyrimidin-5 1honderivate
EP1184383A1 (en) * 2000-09-01 2002-03-06 Sanofi-Synthelabo 9-[Alkyl], 9-[(heteroaryl)alkyl] and 9-[(aryl)alkyl]-2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one derivatives
EP1460075A1 (en) * 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives

Also Published As

Publication number Publication date
JP2006520767A (ja) 2006-09-14
CN1784408A (zh) 2006-06-07
US20080021046A1 (en) 2008-01-24
KR101070149B1 (ko) 2011-10-05
KR20050111782A (ko) 2005-11-28
NO20054330L (no) 2005-12-21
AU2004222596A1 (en) 2004-09-30
CA2518299C (en) 2011-10-25
IL170680A (en) 2012-10-31
ZA200507487B (en) 2006-12-27
TWI330186B (en) 2010-09-11
ES2338325T3 (es) 2010-05-06
HK1086012A1 (en) 2006-09-08
MXPA05010158A (es) 2006-05-19
US7247638B2 (en) 2007-07-24
ATE452892T1 (de) 2010-01-15
TW200504070A (en) 2005-02-01
EP1608654B1 (en) 2009-12-23
CN100358897C (zh) 2008-01-02
AR043658A1 (es) 2005-08-03
US8093256B2 (en) 2012-01-10
WO2004082577A2 (en) 2004-09-30
DE602004024770D1 (de) 2010-02-04
DK1608654T3 (da) 2010-04-26
US20060035885A1 (en) 2006-02-16
NZ542380A (en) 2009-01-31
PL1608654T3 (pl) 2010-07-30
WO2004082577A3 (en) 2004-11-04
IL170680A0 (en) 2009-02-11
SI1608654T1 (sl) 2010-04-30
AU2004222596B2 (en) 2008-08-28
EP1460075A1 (en) 2004-09-22
EA009197B1 (ru) 2007-12-28
PT1608654E (pt) 2010-03-05
CY1109890T1 (el) 2014-09-10
NO20054330D0 (no) 2005-09-20
EA200501315A1 (ru) 2006-04-28
EP1608654A2 (en) 2005-12-28
CA2518299A1 (en) 2004-09-30
BRPI0408591A (pt) 2006-03-21

Similar Documents

Publication Publication Date Title
JP4572195B2 (ja) ８−置換−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体
JP4572194B2 (ja) 置換された８−パーフルオロアルキル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オン誘導体
JP4639182B2 (ja) 置換された８’−ピリジニル−ジヒドロスピロ−［シクロアルキル］−ピリミド［１，２−ａ］ピリミジン−６−オンおよび８’−ピリミジニル−ジヒドロスピロ−［シクロアルキル］−ピリミド［１，２−ａ］ピリミジン−６−オン誘導体
JP5501355B2 (ja) 置換アルキルピリミジン−４−オン誘導体
JP2010189422A (ja) ２−ピリミジニル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オンおよび７−ピリミジニル−２，３−ジヒドロイミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）オン誘導体を含む医薬組成物
JP2010509203A (ja) 置換されている８−ピペリジニル−２−ピリジニル−ピリミド［１，２−ａ］ピリミジン−６−オンおよび８−ピペリジニル−２−ピリミジニル−ピリミド［１，２−ａ］ピリミジン−６−オン誘導体
JP4484524B2 (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
KR100775192B1 (ko) 1-[알킬], 1-[(헤테로아릴)알킬] 및1-[(아릴)알킬]-7-피리디닐-이미다조[1,2-α]피리미딘-5(1Ｈ)-온 유도체
JP4778890B2 (ja) 置換された２−（ジアザ−ビシクロ−アルキル）−ピリミドン誘導体
HK1086012B (en) 8-substituted-6, 7, 8, 9-tetrahydropyrimido[1,2-a] pyrimidin-4-one derivatives
HK1085740B (en) Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido [1,2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido [1,2-a] pyrimidin-6-one derivatives and their use against neurogenerative diseases

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070315

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100720

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100816

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130820

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees